LU87957A1 - Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation - Google Patents

Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation Download PDF

Info

Publication number: LU87957A1
Authority: LU; Luxembourg
Prior art keywords: molecular weight; heparin; mixtures; daltons; ester
Prior art date: 1990-06-26

Application number

LU87957A

Other languages

English (en)

French (fr)

Inventor

Debrie Roger

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-26

Filing date

1991-06-20

Publication date

1993-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9398013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU87957(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-06-20 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1993-01-15 Publication of LU87957A1 publication Critical patent/LU87957A1/fr

Links

239000000203 mixture Substances 0.000 title claims description 53
238000000034 method Methods 0.000 title claims description 26
150000004676 glycans Chemical class 0.000 title claims description 19
229920001282 polysaccharide Polymers 0.000 title claims description 19
239000005017 polysaccharide Substances 0.000 title claims description 19
238000002360 preparation method Methods 0.000 title claims description 15
229920000669 heparin Polymers 0.000 claims description 66
229960002897 heparin Drugs 0.000 claims description 57
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 50
150000002148 esters Chemical class 0.000 claims description 18
230000032050 esterification Effects 0.000 claims description 17
238000005886 esterification reaction Methods 0.000 claims description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
229920000045 Dermatan sulfate Polymers 0.000 claims description 7
230000001225 therapeutic effect Effects 0.000 claims description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
125000001309 chloro group Chemical class Cl* 0.000 claims description 6
229940051593 dermatan sulfate Drugs 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
206010047249 Venous thrombosis Diseases 0.000 claims description 4
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical group ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims description 4
229940073608 benzyl chloride Drugs 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
239000003960 organic solvent Substances 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
239000012736 aqueous medium Substances 0.000 claims description 3
239000002609 medium Substances 0.000 claims description 3
230000002980 postoperative effect Effects 0.000 claims description 3
239000002904 solvent Substances 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
125000001453 quaternary ammonium group Chemical group 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
230000000694 effects Effects 0.000 description 20
239000000047 product Substances 0.000 description 15
230000014508 negative regulation of coagulation Effects 0.000 description 12
239000000243 solution Substances 0.000 description 12
230000002785 anti-thrombosis Effects 0.000 description 8
238000009826 distribution Methods 0.000 description 8
230000001858 anti-Xa Effects 0.000 description 7
239000006185 dispersion Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
-1 heparin ester Chemical class 0.000 description 6
159000000000 sodium salts Chemical class 0.000 description 6
241000894007 species Species 0.000 description 6
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 5
239000012535 impurity Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical class C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 4
239000012634 fragment Substances 0.000 description 4
229960001008 heparin sodium Drugs 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
150000003242 quaternary ammonium salts Chemical class 0.000 description 4
239000012429 reaction media Substances 0.000 description 4
229920001287 Chondroitin sulfate Polymers 0.000 description 3
229920002971 Heparan sulfate Polymers 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
239000012467 final product Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229940127215 low-molecular weight heparin Drugs 0.000 description 3
238000007127 saponification reaction Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000001732 thrombotic effect Effects 0.000 description 3
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
241000282887 Suidae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
108010091395 antiprothrombinase Proteins 0.000 description 2
239000004019 antithrombin Substances 0.000 description 2
229960003872 benzethonium Drugs 0.000 description 2
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
229960001950 benzethonium chloride Drugs 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229940059329 chondroitin sulfate Drugs 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
239000003055 low molecular weight heparin Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
241000283690 Bos taurus Species 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
102100021194 Glypican-6 Human genes 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
230000003024 amidolytic effect Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940107200 chondroitin sulfates Drugs 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229960000610 enoxaparin Drugs 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000013628 high molecular weight specie Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000013627 low molecular weight specie Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
238000004879 turbidimetry Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Polymers & Plastics (AREA)
Materials Engineering (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LU87957A 1990-06-26 1991-06-20 Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation LU87957A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9008013A FR2663639B1 (fr)	1990-06-26	1990-06-26	Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.

Publications (1)

Publication Number	Publication Date
LU87957A1 true LU87957A1 (fr)	1993-01-15

Family

ID=9398013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87957A LU87957A1 (fr)	1990-06-26	1991-06-20	Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation

Country Status (26)

Country	Link
US (1)	US5389618A (de)
JP (1)	JP3287363B2 (de)
KR (1)	KR0185586B1 (de)
AT (1)	AT398976B (de)
AU (1)	AU643531B2 (de)
BE (1)	BE1006827A3 (de)
CA (1)	CA2045433C (de)
CH (1)	CH682236A5 (de)
DK (1)	DK176524B1 (de)
ES (1)	ES2036922B9 (de)
FI (1)	FI104490B (de)
FR (1)	FR2663639B1 (de)
GB (1)	GB2245898B (de)
GR (1)	GR1000763B (de)
HU (1)	HU210925B (de)
IE (1)	IE66341B1 (de)
IL (1)	IL98604A (de)
IT (1)	IT1248557B (de)
LU (1)	LU87957A1 (de)
MX (1)	MX25829A (de)
NL (1)	NL194947C (de)
NO (1)	NO304991B1 (de)
NZ (1)	NZ238691A (de)
PT (1)	PT98102B (de)
SE (1)	SE506267C2 (de)
ZA (1)	ZA914869B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE38743E1 (en)	1990-06-26	2005-06-14	Aventis Pharma S.A.	Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
US5707973A (en) *	1991-04-23	1998-01-13	Rhone-Poulenc Rorer S.A.	Sulfated polysaccharids for treatment or prevention of thromboses
US5849721A (en) *	1992-02-07	1998-12-15	Rhone-Poulenc Rorer S.A.	Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
FR2687158B1 (fr) *	1992-02-07	1995-06-30	Rhone Poulenc Rorer Sa	Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.
DE69429576T2 (de) *	1993-09-30	2002-08-22	Seikagaku Kogyo K.K., Tokio/Tokyo	Dermatansulfatezusammensetzung als antithromotisches mittel
RU2179445C2 (ru) *	1996-08-13	2002-02-20	Бейкер Нортон Фармасьютикалз, Инк.	Способ и композиция для лечения астмы
JP4824170B2 (ja)	1999-04-23	2011-11-30	マサチューセッツインスティテュートオブテクノロジー	ポリマーを表記するためのシステムおよび方法
JP2003504428A (ja) *	1999-06-30	2003-02-04	ハミルトンシビックホスピタルズリサーチディベロップメントインコーポレイテッド	クロット関連凝固因子を阻害するヘパリン組成物
JP4897991B2 (ja) *	1999-07-23	2012-03-14	ラボラトリオスファルマセウティコスロビソシエダッドアノニマ	超低分子量ヘパリン組成物
AU1594801A (en) *	1999-11-12	2001-06-06	Emisphere Technologies, Inc.	Liquid heparin formulation
US6608042B2 (en)	2000-03-28	2003-08-19	Aventis Pharma, S.A.	Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
US6969705B2 (en) *	2000-07-21	2005-11-29	Aventis Pharma S.A.	Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
AU2001291549A1 (en) *	2000-09-08	2002-03-22	Hamilton Civic Hospitals Research Development Inc.	Antithrombotic compositions
AU2002221935A1 (en)	2000-12-16	2002-06-24	Aventis Pharma Deutschland Gmbh	Use of low molecular heparin for treating osteoarthritis
DE10141106A1 (de) *	2001-08-22	2003-03-13	Aventis Pharma Gmbh	Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
JP2005505537A (ja) *	2001-08-28	2005-02-24	レオ・ファーマ・アクティーゼルスカブ	低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物
US7084118B2 (en)	2002-02-22	2006-08-01	Genentech, Inc.	Combination treatment with t-PA variant and low molecular weight heparin
EP1518120A4 (de) *	2002-03-11	2008-08-13	Momenta Pharmaceuticals Inc	Analyse sulfatierter polysaccharide
US20030236221A1 (en) *	2002-06-20	2003-12-25	Chemi Spa	Process for the preparation of esters of heparin
DE60218642T2 (de) *	2002-06-20	2007-11-29	Chemi S.P.A., Cinisello Balsamo	Verfahren zur Herstellung von Heparinestern
US20040265943A1 (en) *	2002-09-23	2004-12-30	Aventis Pharma S.A.	Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
FR2844808B1 (fr) *	2002-09-23	2005-02-25	Aventis Pharma Sa	Methode de determination de groupements specifiques constituant les heparines ou les heparines de bas poids moleculaire
US20040171819A1 (en)	2002-10-10	2004-09-02	Aventis Pharma S.A.	Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US20040147033A1 (en) *	2002-12-20	2004-07-29	Zachary Shriver	Glycan markers for diagnosing and monitoring disease
NZ543717A (en) *	2003-06-05	2008-06-30	Centelion	Administration of a plasmid encoding a fibroblast growth factor (FGF), wherein VEGF-A factor expression is not induced in the myocardial or skeletal muscle to treat myocardial or skeletal angiogenic disorders or defects associated with hypercholesterolemia or diabetes
US7956046B2 (en)	2003-07-24	2011-06-07	Aventis Pharma S.A.	Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
ITMI20031679A1 (it) *	2003-08-29	2005-02-28	Opocrin Spa	Processo per la produzione di eparine a basso peso
US20050186679A1 (en) *	2004-02-24	2005-08-25	Christian Viskov	Method for determining specific groups constituting heparins or low molecular weight heparins
EP1582531A1 (de) *	2004-03-24	2005-10-05	Aventis Pharma S.A.	Verfahren zur Oxydierung nicht-fraktionierten Heparins und die Detektion der Anwesenheit oder Abwesenheit von Glykoserin in Heparin und in von Heparin abgeleiteten Produkten
US20050261241A1 (en) *	2004-05-19	2005-11-24	Celsus Biopharmaceuticals, Inc.	Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
GB0509433D0 (en) *	2005-05-09	2005-06-15	Uni For Milj Og Biovitenskap	Method
EP1792621B1 (de)	2005-11-30	2012-04-04	Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni"	Oral verabreichbare Heparinderivate
US20070154546A1 (en) *	2005-12-30	2007-07-05	Zhang Jack Y	Sustained release pharmaceutical compositions
CN100436483C (zh) *	2006-05-24	2008-11-26	杭州九源基因工程有限公司	一种依诺肝素钠的纯化生产方法
EP2447285A3 (de)	2006-05-25	2013-01-16	Momenta Pharmaceuticals, Inc.	Heparinzusammensetzung mit geringem Molekulargewicht und Anwendungen dafür
US8101733B1 (en)	2006-06-27	2012-01-24	Momenta Pharmaceuticals, Inc.	Methods of evaluating mixtures of polysaccharides
US7968082B1 (en)	2007-01-26	2011-06-28	Momenta Pharmaceuticals, Inc.	Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en)	2007-01-26	2010-09-07	Momenta Pharmaceuticals, Inc.	Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
FR2912409B1 (fr) *	2007-02-14	2012-08-24	Sanofi Aventis	Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
US9139876B1 (en)	2007-05-03	2015-09-22	Momenta Pharmacueticals, Inc.	Method of analyzing a preparation of a low molecular weight heparin
AU2009250803A1 (en) *	2008-05-20	2009-11-26	Crystal Clear Partnership	Separation of polysaccharides by charge density gradient
EP2233145A1 (de)	2009-03-19	2010-09-29	Sanofi-Aventis	AVE5026-Dosis zur Behandlung von venöser Thromboembolie bei Patienten mit starker Nierenfunktionsstörung
ES2817779T3 (es) *	2010-01-19	2021-04-08	Momenta Pharmaceuticals Inc	Evaluación de preparaciones de heparina
CN102792158B (zh)	2011-01-28	2013-07-10	杭州九源基因工程有限公司	一种基于毛细管电泳的依诺肝素钠精细结构测定方法
US9068957B2 (en)	2011-02-21	2015-06-30	Momenta Pharmaceuticals, Inc.	Evaluating heparin preparations
AR085961A1 (es)	2011-04-11	2013-11-06	Sanofi Sa	Polisacaridos que poseen dos sitios de union a la antitrombina iii, metodo para prepararlos y composiciones farmaceuticas que los contienen
CN102603925B (zh) *	2012-03-21	2013-12-11	东营天东制药有限公司	一种由粗品肝素钠直接生产依诺肝素钠的方法
CN102603926B (zh) *	2012-03-27	2014-04-30	烟台东诚生化股份有限公司	一种高效价肝素钠制备新工艺
CN102633908A (zh) *	2012-05-02	2012-08-15	雷晓刚	一种高品质超低分子量肝素的制备方法
RU2512768C1 (ru) *	2012-12-18	2014-04-10	Федеральное бюджетное учреждение "Государственный институт кровезаменителей и медицинских препаратов (ФБУ "ГИКиМП")	Способ получения низкомолекулярного гепарина
CN103145868B (zh) *	2013-01-07	2015-09-16	中国科学院昆明植物研究所	一种低分子量糖胺聚糖衍生物及其药物组合物和其制备方法与应用
CN103175925B (zh) *	2013-03-20	2014-12-03	山东辰中生物制药有限公司	依诺肝素钠生产过程中肝素苄基酯的酯化率的检测方法
CN103214591B (zh) *	2013-04-12	2015-11-04	中国科学院昆明植物研究所	一种含末端2,5-脱水塔罗糖或其衍生物的低分子量糖胺聚糖衍生物
GB2515315A (en) *	2013-06-19	2014-12-24	Dilafor Ab	New Processes
EP3247332A1 (de)	2015-01-20	2017-11-29	Incarda Therapeutics, Inc.	Einheitsaerosoldosen für antikoagulation
CN109666086B (zh) *	2018-11-05	2020-12-22	上海宝维医药技术有限公司	一种高纯度肝素季铵盐的制备方法及其应用
WO2022015794A1 (en)	2020-07-14	2022-01-20	Optimvia, Llc	Methods for synthesizing non-anticoagulant heparan sulfate
CA3144968A1 (en)	2019-07-09	2021-01-14	Optimvia Llc	Methods for synthesizing anticoagulant polysaccharides
WO2026057760A1 (en)	2024-09-13	2026-03-19	Sanofi	Uses and methods for in situ generating paps from cyclo-paps using a cell free extract
WO2026057759A1 (en)	2024-09-13	2026-03-19	Sanofi	Novel bioengineered heparins, low molecular weight heparins derived thereof, and their method of production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK108622C (da) *	1963-01-18	1968-01-15	Roussel Uclaf	Fremgangsmåde til fremstilling af benzylheparinat eller dets alkalimetalsalte.
FR2482611B1 (fr) *	1980-05-14	1986-03-07	Pharmindustrie	Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) *	1980-05-19	1982-09-28	Riker Laboratories, Inc.	Anticoagulant substance
FR2503714B1 (fr) *	1981-04-10	1986-11-21	Choay Sa	Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
DE3265781D1 (en) *	1981-05-21	1985-10-03	Akzo Nv	New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions
FR2548672A1 (fr) *	1983-07-04	1985-01-11	Pharmuka Lab	Oligosaccharides sulfates et leur utilisation comme medicaments
DK196886D0 (da) *	1986-04-30	1986-04-30	Novo Industri As	Fremstilling af polysaccharider
IT1213384B (it) *	1986-11-24	1989-12-20	Lab Derivati Organici Mediolan	Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
FR2614026B1 (fr) *	1987-04-16	1992-04-17	Sanofi Sa	Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
ES2006891A6 (es) *	1988-04-09	1989-05-16	Bioiberica	Procedimiento de preparacion de fracciones de oligosacaridos por depolimerizacion quimica controlada de heparina.
EP0337327A1 (de) *	1988-04-09	1989-10-18	Bioiberica, S.A.	Verfahren zur Herstellung von neuen Oligosaccharid-Fragmenten durch kontrollierte chemische Depolymerisation von Heparin
US4981955A (en) *	1988-06-28	1991-01-01	Lopez Lorenzo L	Depolymerization method of heparin
US5011919A (en) *	1989-01-30	1991-04-30	Ajorca S.A.	Modified heparins and obtention process
IT1243300B (it) *	1990-12-20	1994-05-26	Fidia Spa	Derivati dell'eparina

1990
- 1990-06-26 FR FR9008013A patent/FR2663639B1/fr not_active Expired - Lifetime
1991
- 1991-05-17 MX MX2582991A patent/MX25829A/es unknown
- 1991-06-18 NL NL9101049A patent/NL194947C/nl not_active IP Right Cessation
- 1991-06-19 GR GR910100270A patent/GR1000763B/el not_active IP Right Cessation
- 1991-06-20 LU LU87957A patent/LU87957A1/fr unknown
- 1991-06-24 AU AU79288/91A patent/AU643531B2/en not_active Expired
- 1991-06-24 GB GB9113589A patent/GB2245898B/en not_active Expired - Lifetime
- 1991-06-24 IL IL9860491A patent/IL98604A/en not_active IP Right Cessation
- 1991-06-25 CH CH1884/91A patent/CH682236A5/fr not_active IP Right Cessation
- 1991-06-25 ZA ZA914869A patent/ZA914869B/xx unknown
- 1991-06-25 FI FI913101A patent/FI104490B/fi not_active IP Right Cessation
- 1991-06-25 CA CA002045433A patent/CA2045433C/fr not_active Expired - Lifetime
- 1991-06-25 SE SE9101957A patent/SE506267C2/sv not_active IP Right Cessation
- 1991-06-25 KR KR1019910010600A patent/KR0185586B1/ko not_active Expired - Lifetime
- 1991-06-25 IE IE221691A patent/IE66341B1/en not_active IP Right Cessation
- 1991-06-25 NO NO912485A patent/NO304991B1/no not_active IP Right Cessation
- 1991-06-25 DK DK199101243A patent/DK176524B1/da not_active IP Right Cessation
- 1991-06-25 NZ NZ238691A patent/NZ238691A/en not_active IP Right Cessation
- 1991-06-25 HU HU912122A patent/HU210925B/hu unknown
- 1991-06-25 BE BE9100607A patent/BE1006827A3/fr not_active IP Right Cessation
- 1991-06-25 ES ES009101505A patent/ES2036922B9/es not_active Expired - Fee Related
- 1991-06-25 JP JP17903091A patent/JP3287363B2/ja not_active Expired - Fee Related
- 1991-06-26 IT ITMI911757A patent/IT1248557B/it active IP Right Grant
- 1991-06-26 PT PT98102A patent/PT98102B/pt not_active IP Right Cessation
- 1991-06-26 AT AT0128191A patent/AT398976B/de not_active IP Right Cessation
1993
- 1993-07-16 US US08/092,577 patent/US5389618A/en not_active Ceased

Also Published As

Publication number	Publication date
ITMI911757A1 (it)	1992-12-26
MX25829A (es)	1993-10-01
CA2045433C (fr)	2002-07-30
KR0185586B1 (ko)	1999-04-01
DK124391A (da)	1991-12-27
JPH04226101A (ja)	1992-08-14
NL194947B (nl)	2003-04-01
NL194947C (nl)	2003-08-04
US5389618A (en)	1995-02-14
CA2045433A1 (fr)	1991-12-27
AU7928891A (en)	1992-01-02
FR2663639A1 (fr)	1991-12-27
PT98102A (pt)	1992-03-31
GR1000763B (el)	1992-12-30
FR2663639B1 (fr)	1994-03-18
KR920000792A (ko)	1992-01-29
AU643531B2 (en)	1993-11-18
ES2036922B1 (es)	1994-03-01
IE912216A1 (en)	1992-01-01
DK176524B1 (da)	2008-07-14
HU210925B (en)	1995-09-28
IL98604A (en)	1998-08-15
JP3287363B2 (ja)	2002-06-04
SE9101957L (sv)	1991-12-27
NO304991B1 (no)	1999-03-15
SE506267C2 (sv)	1997-11-24
ITMI911757A0 (it)	1991-06-26
IE66341B1 (en)	1995-12-27
NO912485L (no)	1991-12-27
SE9101957D0 (sv)	1991-06-25
CH682236A5 (de)	1993-08-13
FI913101A0 (fi)	1991-06-25
GB2245898A (en)	1992-01-15
FI913101L (fi)	1991-12-27
GB9113589D0 (en)	1991-08-14
FI104490B (fi)	2000-02-15
NL9101049A (nl)	1992-01-16
IL98604A0 (en)	1992-07-15
DK124391D0 (da)	1991-06-25
ATA128191A (de)	1994-07-15
NO912485D0 (no)	1991-06-25
ZA914869B (en)	1992-04-29
PT98102B (pt)	1998-11-30
HUT57796A (en)	1991-12-30
ES2036922A1 (es)	1993-06-01
IT1248557B (it)	1995-01-19
GB2245898B (en)	1993-10-06
ES2036922B9 (es)	2012-07-30
BE1006827A3 (fr)	1995-01-03
NZ238691A (en)	1992-07-28
AT398976B (de)	1995-02-27
GR910100270A (en)	1992-08-25

Publication	Publication Date	Title
BE1006827A3 (fr)	1995-01-03	Melanges de polysaccharides de bas poids moleculaires, procede de preparation et utilisation.
EP0287477B1 (de)	1994-11-02	Heparine mit niedrigem Molekulargewicht und regelmässiger Struktur, ihre Herstellung und biologische Verwendungen
EP0403377B1 (de)	1995-12-06	Sulfatierte Polysaccharide, Antikoagulierungs- und Antikomplementärmittel, hergestellt aus Fukanen aus braunen Algen, und Verfahren zu deren Herstellung
EP0214879B1 (de)	1990-11-22	Verfahren zur Sulphatierung von Glykosaminoglykanen, daraus hergestellte Glykosaminoglykane und ihre biologischen Verwendungen
EP0428182B1 (de)	1994-08-24	Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen
EP0040144A1 (de)	1981-11-18	Sulfatisierte Polysaccharide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2501546C (fr)	2012-04-03	Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
FR2538404A1 (de)	1984-06-29
WO2008113919A1 (fr)	2008-09-25	Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine, leur procede de preparation et leur utilisation
CA2468759C (fr)	2011-08-02	Procede de sulfonation de composes comprenant des groupements hydroxyles (oh) libres ou des amines primaires ou secondaires
EP0625166B1 (de)	1997-09-10	Sulfatierte polysaccharide, verfahren zu deren herstellung, pharmazeutische zusammensetzung und ihre verwendung
CA2678166A1 (fr)	2008-09-25	Heparines comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine, leur procede de preparation et leur utilisation
CA2533555A1 (fr)	2005-02-03	Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
FR2675806A1 (fr)	1992-10-30	Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.
EP0138632A2 (de)	1985-04-24	Komplexe, welche Oligosaccharide enthalten, ihre Herstellung und ihre biologische und biochemische Verwendung
EP0181252A1 (de)	1986-05-14	Verfahren zur Herstellung von Mukopolysaccharidzusammensetzungen welche eine hohe antithrombogene Aktivität besitzen